Surgery Partners (NASDAQ:SGRY) Downgraded by Zacks Research to Hold
Zacks Research downgraded Surgery Partners (NASDAQ:SGRY) from "Strong Buy" to "Hold," leading to a 6% drop in the stock price despite the company exceeding Q2 earnings and revenue estimates. While the broader analyst consensus remains a "Moderate Buy" with an average target of $19.45, …